Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – ...
A new study led by Dr. Jack Tseng, published in PeerJ, has shed light on the intricate relationship between tooth wear and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback